In October 2018, the National Test Directory (NTD) for Cancer was published.

The National Test Directory is updated each year to ensure access to the latest diagnostics and treatments. The NTD specifies which genomic tests are commissioned by the NHS in England, the clinical indication for which they apply and the technology by which the tests will be delivered.

Access to genomic services for HaemOnc patients will continue to be through your Specialist Integrated Haematological Malignancy Diagnostic Service (SIHMDS).

The NE&Y GLH cover three regional SIHMDS groups:

  1. North East Haematological Oncology Diagnostic Service
  2. Sheffield Haematological Oncology Diagnostic Service
  3. Haematological Malignancy Diagnostic Service Leeds

Genomic haemato-oncology diagnostics are funded centrally by NHSE and so referring Trusts will not be charged for these services if they refer testing to their designated local GLH.

Note. Non-genetic activity carried out within an SIHMDS is funded separately and will still be charged for.

The Haemato-Oncology Team

Prof John Snowden
HaemOnc Lead Clinician
0114 2713357
[email protected]

Dr Catherine Cargo
HaemOnc Lead Clinician

Polly Talley
HaemOnc Lead Scientist
[email protected]


Gavin Cuthbert
[email protected]

Angharad Goodman
[email protected]


Rebecca Pollitt
[email protected]

Harveer Cheema
[email protected]


Paul Evans
[email protected]

Phil Dean
[email protected]